Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono"), today announced that the results from the open label Phase 2 PROSPECT Study of tirabrutinib is to be ...

In an analysis with time censoring, early BCR was reported in 69 patients (29 ... coupled with androgen deprivation therapy and androgen receptor signaling inhibitors. Dr Viti’s team found ...

DZD8586 demonstrated significant anti-tumor efficacy in heavily pretreated chronic lymphocytic leukemia/small lymphocytic ...

Astellas & Pfizer’s Xtandi shows long-term overall survival in metastatic hormone-sensitive prostate cancer: Tokyo Saturday, May 24, 2025, 13:00 Hrs [IST] Astellas Pharma Inc. a ...

Terns Pharmaceuticals, Inc.’s TERN share price has surged by 11.67%, which has investors questioning if this is right time to sell.

Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. today announced longer-term follow-up results from an open-label extension of the Phase 3 ARCHES ...

Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is an important factor from a complex downstream ...

ILC accounts for 10–15% of breast cancers and often goes undetected. Learn about its characteristics, treatments, and future ...

Now, researchers have taken a decisive step towards understanding how. “This single receptor is responsible for our insatiable, never-ending attraction to sugar,” says Columbia neuroscientist ...

The latest data from studies across Bayer’s oncology and women’s health portfolios will be presented at the upcoming 2025 ...